Perspective Therapeutics Inc. (CATX)vsEdwards Lifesciences Corp (EW)
CATX
Perspective Therapeutics Inc.
$4.29
+1.18%
HEALTHCARE · Cap: $507.00M
EW
Edwards Lifesciences Corp
$82.67
+1.20%
HEALTHCARE · Cap: $48.01B
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 686280% more annual revenue ($6.07B vs $884,000). EW leads profitability with a 17.7% profit margin vs 0.0%. EW earns a higher WallStSmart Score of 55/100 (C).
CATX
Avoid24
out of 100
Grade: F
EW
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CATX.
Margin of Safety
-544.4%
Fair Value
$12.31
Current Price
$82.67
$70.36 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Strong operational efficiency at 23.7%
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -41.6% — below average capital efficiency
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Earnings declined 76.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : CATX
The strongest argument for CATX centers on Debt/Equity, Altman Z-Score, Price/Book.
Bull Case : EW
The strongest argument for EW centers on Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 23.7%. Revenue growth of 13.3% demonstrates continued momentum.
Bear Case : CATX
The primary concerns for CATX are EPS Growth, Market Cap, Profit Margin.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 45.7x leaves little room for execution misses.
Key Dynamics to Monitor
CATX profiles as a value stock while EW is a mature play — different risk/reward profiles.
CATX carries more volatility with a beta of 1.80 — expect wider price swings.
EW is growing revenue faster at 13.3% — sustainability is the question.
EW generates stronger free cash flow (354M), providing more financial flexibility.
Bottom Line
EW scores higher overall (55/100 vs 24/100), backed by strong 17.7% margins and 13.3% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Perspective Therapeutics Inc.
HEALTHCARE · MEDICAL DEVICES · USA
Perspective Therapeutics Inc. is an innovative biotechnology company specializing in the development of next-generation radiopharmaceuticals designed to treat various types of cancer. Utilizing cutting-edge radioisotope technologies, the company aims to enhance the efficacy of cancer treatments, thereby improving patient outcomes in a rapidly evolving market for targeted therapies. With a strong leadership team and strategic partnerships, Perspective Therapeutics is well-equipped to advance its mission and deliver breakthrough solutions that address the growing need for effective cancer interventions.
Visit Website →Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?